company background image
IMGO

Imago BioSciences NasdaqGS:IMGO Stock Report

Last Price

US$35.86

Market Cap

US$1.2b

7D

0.4%

1Y

101.5%

Updated

07 Dec, 2022

Data

Company Financials +
IMGO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IMGO Stock Overview

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow.

Imago BioSciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Imago BioSciences
Historical stock prices
Current Share PriceUS$35.86
52 Week HighUS$35.89
52 Week LowUS$11.56
Beta0
1 Month Change121.22%
3 Month Change117.99%
1 Year Change101.46%
3 Year Changen/a
5 Year Changen/a
Change since IPO120.13%

Recent News & Updates

Imago BioSciences (NASDAQ:IMGO) Is In A Good Position To Deliver On Growth Plans

Nov 08
Imago BioSciences (NASDAQ:IMGO) Is In A Good Position To Deliver On Growth Plans

Recent updates

Imago BioSciences (NASDAQ:IMGO) Is In A Good Position To Deliver On Growth Plans

Nov 08
Imago BioSciences (NASDAQ:IMGO) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Situation

Jul 26
Here's Why We're Not Too Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Situation

Companies Like Imago BioSciences (NASDAQ:IMGO) Are In A Position To Invest In Growth

Apr 12
Companies Like Imago BioSciences (NASDAQ:IMGO) Are In A Position To Invest In Growth

We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Rate

Dec 08
We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Rate

Shareholder Returns

IMGOUS BiotechsUS Market
7D0.4%1.9%-0.4%
1Y101.5%-11.2%-20.6%

Return vs Industry: IMGO exceeded the US Biotechs industry which returned -6.5% over the past year.

Return vs Market: IMGO exceeded the US Market which returned -17.6% over the past year.

Price Volatility

Is IMGO's price volatile compared to industry and market?
IMGO volatility
IMGO Average Weekly Movement30.8%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: IMGO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 31% a week.

Volatility Over Time: IMGO's weekly volatility has increased from 18% to 31% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201241Hugh Rienhoffhttps://www.imagobio.com

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Imago BioSciences, Inc. Fundamentals Summary

How do Imago BioSciences's earnings and revenue compare to its market cap?
IMGO fundamental statistics
Market CapUS$1.21b
Earnings (TTM)-US$61.64m
Revenue (TTM)n/a

0.0x

P/S Ratio

-19.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMGO income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$61.64m
Earnings-US$61.64m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.82
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did IMGO perform over the long term?

See historical performance and comparison